Telmisartan improves vascular function and reduces platelet activation in rats with streptozotocin-induced diabetes mellitus

Pharmacological Research

Volumn 56, Issue 3, 2007, Pages 217-223

  Schäfer, Andreas ^a   Flierl, Ulrike ^a   Vogt, Christian ^a   Menninger, Stefanie ^a   Tas, Piet ^b   Ertl, Georg ^a   Bauersachs, Johann ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Angiotensin II; Diabetes; Endothelial dysfunction; Nitric oxide; Platelets

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN II; ENDOTHELIUM DERIVED RELAXING FACTOR; FIBRINOGEN; NITRIC OXIDE DONOR; STREPTOZOCIN; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; BIOAVAILABILITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; INTESTINE PRESSURE; MALE; NONHUMAN; PHOSPHOPROTEIN PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; REDUCTION; STREPTOZOCIN DIABETES; THROMBOCYTE ACTIVATION; VASCULAR DISEASE;

ACETYLCHOLINE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BENZIMIDAZOLES; BENZOATES; BLOOD PLATELETS; CELL ADHESION MOLECULES; DIABETES MELLITUS, EXPERIMENTAL; DIETHYLAMINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; MALE; MICROFILAMENT PROTEINS; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE; NITROARGININE; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET ACTIVATION; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; VASODILATION; VASODILATOR AGENTS;

EID: 34548293808     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2007.05.009     Document Type: Article

References (39)

1. Tschoepe D., and Menart-Houtermans B. Diabetes mellitus. In: Michelson A.D. (Ed). Platelets (2002), Academic Press, San Diego 435-445
2. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
3. Hu F.B., Stampfer M.J., Haffner S.M., Solomon C.G., Willett W.C., and Manson J.E. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabet Care 25 (2002) 1129-1134
4. Wagenknecht L.E., Zaccaro D., Espeland M.A., Karter A.J., O'Leary D.H., and Haffner S.M. Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 23 (2003) 1035-1041
5. Guerci B., Bohme P., Kearney-Schwartz A., Zannad F., and Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2. Altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabet Metab 27 (2001) 436-447
6. Schäfer A., Wiesmann F., Neubauer S., Eigenthaler M., Bauersachs J., and Channon K.M. Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 109 (2004) 1819-1822
7. Schäfer A., Alp N.J., Cai S., Lygate C.A., Neubauer S., Eigenthaler M., et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol 24 (2004) 1720-1726
8. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88 (2001) 756-762
9. Massberg S., Brand K., Gruner S., Page S., Muller E., Muller I., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196 (2002) 887-896
10. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
11. Lewis E.J., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
12. Burnier M., and Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 24 (2006) 11-25
13. Schäfer A., Fraccarollo D., Hildemann S., Christ M., Eigenthaler M., Kobsar A., et al. Inhibition of platelet activation in congestive heart failure by selective aldosterone receptor antagonism and ACE inhibition: role of endothelial function and platelet VASP phosphorylation. Thromb Haemost 89 (2003) 1024-1030
14. Schäfer A., Fraccarollo D., Eigenthaler M., Tas P., Firnschild A., Frantz S., et al. Rosuvastatin reduces platelet activation in heart failure: role of nitric oxide bioavailability. Arterioscler Thromb Vasc Biol 25 (2005) 1071-1077
15. Schäfer A., Fraccarollo D., Hildemann S., Tas P., Ertl G., and Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial function. Cardiovasc Res 58 (2003) 655-662
16. 2+-independent activation of the endothelial nitric oxide synthase. Proc Natl Acad Sci USA 96 (1999) 1123-1128
17. Landmesser U., Harrison D., and Drexler H. Oxidant stress-a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 62 (2006) 13-19
18. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
19. Alp N.J., Mussa S., Khoo J., Cai S., Guzik T., Jefferson A., et al. Tetrahydrobiopterin-dependent preservation of nitric oxide-mediated endothelial function in diabetes by targeted transgenic GTP-cyclohydrolase I over-expression. J Clin Invest 112 (2003) 725-735
20. Guzik T.J., Mussa S., Gastaldi D., Sadowski J., Ratnatunga C., Pillai R., et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105 (2002) 1656-1662
21. Kalinowski L., Dobrucki L.W., Brovkovych V., and Malinski T. Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin. Circulation 105 (2002) 933-938
22. Pannirselvam M., Verma S., Anderson T.J., and Triggle C.R. Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol 136 (2002) 255-263
23. Cai S., Khoo J., Mussa S., Alp N.J., and Channon K.M. Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48 (2005) 1933-1940
24. Mollnau H., Wendt M., Szocs K., Lassegue B., Schulz E., Oelze M., et al. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90 (2002) E58-E65
25. Hunt K.J., Williams K., Rivera D., O'Leary D.H., Haffner S.M., Stern M.P., et al. Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. Arterioscler Thromb Vasc Biol 23 (2003) 1845-1850
26. Resnick H.E., Harris M.I., Brock D.B., and Harris T.B. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabet Care 23 (2000) 176-180
27. Huo Y., Schober A., Forlow S.B., Smith D.F., Hyman M.C., Jung S., et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9 (2003) 61-67
28. Utsugisawa K., Kizawa H., Nagane Y., Kondoh R., Iwa Y., Akutsu H., et al. Biphasic effects of angiotensin II and receptor antagonism on aggregability and protein kinase C phosphorylation in human platelets. Thromb Haemost 94 (2005) 1012-1018
29. Savoia C., Touyz R.M., Endemann D.H., Pu Q., Ko E.A., De Ciuceis C., et al. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients. Hypertension 48 (2006) 271-277
30. Schäfer A., Flierl U., Kobsar A., Eigenthaler M., Ertl G., and Bauersachs J. Soluble guanylyl cyclase activation with HMR 1766 attenuates platelet activation in diabetic rats. Arterioscler Thromb Vasc Biol 26 (2006) 2813-2818
31. Andraws R., and Brown D.L. Effect of inhibition of the renin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99 (2007) 1006-1012
32. Abuissa H., Jones P.G., Marso S.P., and O'Keefe J.H. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 46 (2005) 821-826
33. Berkenboom G., Brekine D., Unger P., Grosfils K., Staroukine M., and Fontaine J. Chronic angiotensin-converting enzyme inhibition and endothelial function of rat aorta. Hypertension 26 (1995) 738-743
34. Mukai Y., Shimokawa H., Higashi M., Morikawa K., Matoba T., Hiroki J., et al. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol 22 (2002) 1445-1450
35. Benson S.C., Pershadsingh H.A., Ho C.I., Chittiboyina A., Desai P., Pravenec M., et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR{gamma}-modulating activity. Hypertension 43 (2004) 993-1002
36. Benndorf R.A., Rudolph T., Appel D., Schwedhelm E., Maas R., Schulze F., et al. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55 (2006) 1159-1164
37. Derosa G., Fogari E., D'Angelo A., Cicero A.F., Salvadeo S.A., Ragonesi P.D., et al. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 32 (2007) 261-268
38. Derosa G., Cicero A.F., D'Angelo A., Ragonesi P.D., Ciccarelli L., Piccinni M.N., et al. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. Hypertens Res 29 (2006) 849-856
39. Ceriello A., Piconi L., Esposito K., and Giugliano D. Telmisartan shows an equivalent effect of vitamin C in further improving endothelial dysfunction after glycemia normalization in type 1 diabetes. Diabet Care (2007)